Peptides in Oncology Research
Educational profiles of peptides and compounds studied in the published oncology literature. Each profile summarizes mechanisms of action, the state of investigational evidence, and links to laboratory-grade sourcing references. Educational only — not medical advice, not treatment guidance.
Thymosin Alpha 1 (TA1)
≥98%Immune modulation; enhances T-cell response
Lung, melanoma, adjunct to chemotherapy
A powerful immune-modulating peptide that enhances T-cell function and has shown promise in cancer immunotherapy research.
Curcumin
≥95%Anti-inflammatory, antioxidant, induces apoptosis
Breast, colon, prostate, pancreatic
Natural compound with potent anti-inflammatory and anti-cancer properties, widely studied for its tumor-suppressive effects.
BPC 157
≥98%Tissue repair, angiogenesis modulation
Wound healing, potential anti-metastatic effects
Body Protection Compound with remarkable healing properties and potential applications in cancer research.
Epithalon (10 mg)
≥99%Telomerase activation, cellular regeneration
Anti-aging, DNA regulation, cancer prevention
Primarily studied for anti-aging properties, showing promise in cancer prevention and DNA regulation research.
LL-37 Complex (5 mg)
≥97%Antimicrobial peptide with direct cytotoxic effects on cancer cells
Breast, lung, ovarian, colon cancer
Human cathelicidin peptide that selectively targets cancer cells through membrane disruption while enhancing immune system recognition of tumors. Shows potent anti-cancer activity by inducing apoptosi...
DSIP (Delta-Sleep-Inducing Peptide, 5 mg)
≥95%Sleep regulation, neuroprotection
Ongoing studies in cancer treatment
Neuropeptide with sleep-inducing properties and emerging research in cancer treatment applications.
Gonadorelin (10 mg)
≥98%GnRH receptor agonist, hormonal regulation
May slow growth of certain cancers
Synthetic gonadotropin-releasing hormone with potential in hormone-dependent cancer research.
PNC-28 (20 mg)
≥98%Tumor-penetrating peptide; targets HDM-2 protein
Breast, pancreatic, melanoma, solid tumors
Advanced tumor-penetrating peptide derived from p53 protein. PNC-28 selectively enters cancer cells and induces necrosis by targeting the HDM-2 protein, showing promising results in solid tumor resear...
Fenbendazole
Research gradeMicrotubule destabilization; inhibits glucose uptake
Multiple cancer types, particularly studied in lymphoma, lung, and colon cancer
Anthelmintic compound showing promising anti-cancer properties in research studies. Fenbendazole works by disrupting microtubule formation and blocking glucose uptake in cancer cells, potentially inhi...
Methylene Blue
Pharmaceutical GradePhotodynamic therapy agent, mitochondrial enhancer
Cancer photodynamic therapy, antimicrobial research
Methylene blue is a versatile compound used in photodynamic therapy research and as a mitochondrial enhancer. Shows promise in cancer research applications and antimicrobial studies.
Antineoplastons (A10)
Research gradeBiochemical defense system that re-programs cancer cells without destroying normal cells
Brain tumors, various solid tumors - targets neoplastic cells while preserving healthy tissue
Revolutionary peptide-based cancer treatment discovered by Dr. Stanislaw Burzynski in 1967. Antineoplastons are naturally occurring peptides that demonstrate the ability to reprogram cancer cells thro...
Acemannan
Natural extractPolysaccharide that enhances immune response and raises T-cell counts
Multiple cancer types - enhances immune system recognition and T-cell activity against tumors
Acemannan is a powerful polysaccharide derived from Aloe Vera that shows promising results in cancer treatment by enhancing immune response and raising T-cell counts. Research demonstrates its potenti...
Important Disclaimer
The compounds listed on this page are presented for educational and research purposes only. They are investigational and not FDA-approved for the treatment of cancer or any other condition. Nothing on this page constitutes medical advice. Consult qualified healthcare professionals before making any health-related decisions.
